Market Place
Sourcing Support
U.S. Renal Care Enrolls First Patients in VOICE Vafseo® Trial
03 Dec 2024 //
PR NEWSWIRE
Vadadustat Study Published in American Journal of Kidney Disease
14 Nov 2024 //
PR NEWSWIRE
Akebia Signs Supply Contract For Vafseo® Access In Dialysis
22 Oct 2024 //
PR NEWSWIRE
CMS Grants TDAPA Reimbursement For Vafseo From January 2025
10 Oct 2024 //
PR NEWSWIRE
Akebia And U.S. Renal Care Sign Supply Contract For Vafseo
07 Oct 2024 //
PR NEWSWIRE
Akebia Therapeutics and U.S. Renal Care Initiate VOICE Trial of Vafseo®
05 Sep 2024 //
PR NEWSWIRE
Akebia Therapeutics Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
PR NEWSWIRE
Akebia unveils IRA-driven high price for Vafseo
12 Jul 2024 //
FIERCE PHARMA
Akebia Updates On Momentum Of Vafseo® (Vadadustat) Commercial Launch
11 Jul 2024 //
PR NEWSWIRE
Akebia Therapeutics To Present At H.C. Wainwright 3rd Annual Kidney Conference
27 Jun 2024 //
PR NEWSWIRE
Akebia Therapeutics Q1 2024 Financials, Business Highlights
09 May 2024 //
PR NEWSWIRE
Vafseo® Approved by The U.S. Fda for The Treatment of Anemia
28 Mar 2024 //
PR NEWSWIRE
U.S. FDA approves Akebia`s anemia drug
28 Mar 2024 //
REUTERS
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets
27 Mar 2024 //
PR NEWSWIRE
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
28 Sep 2023 //
PR NEWSWIRE
Akebia Announces Approval of Vafseo in Australia and Provides Commercial Update
26 Sep 2023 //
PR NEWSWIRE
After high-profile snub, Akebia plots vadadustat resubmission
24 Aug 2023 //
FIERCE PHARMA
Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023
18 Jul 2023 //
PR NEWSWIRE
Akebia Announces Swissmedic Approval of Vafseo® (vadadustat)
20 Jun 2023 //
PR NEWSWIRE
Akebia`s Vafseo (Vadadustat) Receives Approval in the Europe
31 May 2023 //
EMA
Akebia to refile anemia drug vadadustat after FDA denied appeal
31 May 2023 //
ENDPTS
Akebia Enters into Agreement with Medice Arzneimittel Pütter GmbH&Co.KG
25 May 2023 //
PR NEWSWIRE
Akebia Announces UK MHRA Approval of Vafseo® (vadadustat)
22 May 2023 //
PR NEWSWIRE
EU regulators clear Akebia`s renal anaemia therapy Vafseo
26 Apr 2023 //
PR NEWSWIRE
Akebia touts new data on anemia drug a year after rejection
04 Apr 2023 //
ENDPTS
Akebia Announces Positive Results from Vadadustat Alternative Dosing Study
03 Apr 2023 //
PR NEWSWIRE
Akebia proposes new dosing for oral anemia drug amid FDA dispute
03 Apr 2023 //
FIERCE PHARMA
Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat
30 Mar 2023 //
PR NEWSWIRE
After FDA snub, Akebia`s oral anemia drug Vafseo nears EU nod
28 Feb 2023 //
FIERCE PHARMA
Akebia Receives Positive CHMP Opinion in Europe for Vafseo
23 Feb 2023 //
PR NEWSWIRE
Akebia says FDA staffing issues are delaying appeal process
22 Feb 2023 //
FIERCE BIOTECH
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat
22 Dec 2022 //
PRNEWSWIRE
Akebia is taking the fight to the FDA months after rejection
05 Nov 2022 //
FIERCEBIOTECH
Akebia Regaining Rights to Vadadustat in US, Europe, China and more
30 Jun 2022 //
PRNEWSWIRE
Akebia Terminates License Agreements with Otsuka
17 May 2022 //
BIOSPACE
Akebia to lay off 42% of workforce, suspend trials after FDA drug rejection
08 Apr 2022 //
BIOPHARMADIVE
U.S. FDA declines to approve Akebia`s anemia drug on safety concerns
31 Mar 2022 //
REUTERS
Novartis, BMS, Innovent, Lilly, Akebia await FDA decisions
03 Mar 2022 //
FIERCEPHARMA
Akebia scrapes together $85M war chest to commercialize vada as PDUFA date looms
24 Feb 2022 //
ENDPTS
Akebia Tx Announces Amendment of License Agreement with Vifor Pharma
22 Feb 2022 //
PRESS RELEASE
Akebia Therapeutics Announces Amendment of License Agreement with Vifor
22 Feb 2022 //
PRESS RELEASE
GSK pulls off clean sweep of endpoint hits in anemia phase 3
09 Nov 2021 //
FIERCEBIOTECH
Akebia Announces Vadadustat Efficacy and Safety Data to be Presented
18 Oct 2021 //
PRNEWSWIRE
Akebia sees first-in-class opening for roxadustat rival: CEO
17 Aug 2021 //
FIERCEPHARMA
Akebia CEO aims to seize first-in-class opening with vadadustat
16 Aug 2021 //
FIERCEPHARMA
New England Journal of Medicine Publishes Results of Global Phase 3 Clinical
29 Apr 2021 //
PRNEWSWIRE
New England Journal of Medicine Publishes Results of Global Phase 3
28 Apr 2021 //
BIOSPACE
Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat
23 Oct 2020 //
PRNEWSWIRE
Akebia shares MACEd as their PhIII anemia drug fails on safety
03 Sep 2020 //
ENDPTS
Akebia Therapeutics Announces Results from its PRO2TECT Global Phase 3 Program
02 Sep 2020 //
PRNEWSWIRE
Akebia Therapeutics Announces First Commercial Launch of VAFSEO™
26 Aug 2020 //
PRESS RELEASE
Akebia Therapeutics Announces First Commercial Launch of VAFSEO™
26 Aug 2020 //
PRNEWSWIRE
Akebia Announces Initiation of Investigator-Sponsored Evaluating Vadadustat
14 Jul 2020 //
PRNEWSWIRE
Akebia Announces Approval of Vadadustat in Japan for the Treatment of Anemia
29 Jun 2020 //
PRESS RELEASE
Why Akebia Therapeutics Stock Is Crushing It Today
05 May 2020 //
NASDAQ
Akebia Announced Positive Top-Line Results from Global Ph3 Program of Vadadustat
05 May 2020 //
PR NEWSWIRE
Vifor`s Announces Akebia’s +ve Top-Line Results From Global Phase-III vadadustat
04 May 2020 //
BIOSPACE
Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat
11 Nov 2019 //
BUSINESSWIRE
Akebia Announces Full Enrollment of its Global Ph3 Program of Vadadustat
03 Sep 2019 //
BUSINESSWIRE
First regulatory filing for vadadustat boosts Akebia Therapeutics
24 Jul 2019 //
THE PHARMALETTER
